BCP may act on multiple targets, many of which are included in NAFLD and metabolic syndrome, since it is able to reduce lipid accumulation in hepatocytes but also in adipocytes [53], may improve muscle insulin resistance [12] and systemic inflammation, therefore resulting in a greater overall improvement compared with compounds with a more liver-restricted mode of action. The gene discussed is INS; the disease is metabolic dysfunction-associated steatotic liver disease.